There are 142 resources available
Second vote and conclusions
Presenter: Robert Coleman
Session: How hot is HIPEC treatment in ovarian cancer?
Resources:
Slides
Webcast
Where are we now? Latest advances in treatment of gynecologic cancer
Presenter: Ana Oaknin
Session: GSK - Shifting the treatment paradigm of OC/EC: Towards a new horizon
Resources:
Webcast
Where are we going with OC? Evolving the management of 1L advanced ovarian cancer with PARPis
Presenter: Iain McNeish
Session: GSK - Shifting the treatment paradigm of OC/EC: Towards a new horizon
Resources:
Webcast
Where are we going with EC? Aiming to improve outcomes in primary advanced or recurrent endometrial cancer with PD-(L)1 inhibitors
Presenter: Ainhoa Madariaga Urrutia
Session: GSK - Shifting the treatment paradigm of OC/EC: Towards a new horizon
Resources:
Webcast
Live Q&A and discussion
Presenter: All Speakers
Session: GSK - Shifting the treatment paradigm of OC/EC: Towards a new horizon
Resources:
Webcast
2P - Outcomes of patients with gynecological tumors harboring HER2 defects: a single center study based on Gustave Roussy cancer center’s molecular program
Presenter: Cyril Roussel-Simonin
Session: Poster Display session
3P - NaPi2b Expression in High Grade Serous Ovarian Cancer: results from combined data sets
Presenter: Susana Banerjee
Session: Poster Display session
4P - Evaluation of Antitumor Activity and Immunogenic Cell Death (ICD) Induction by MORAb-202 (Farletuzumab Ecteribulin) in Human Ovarian Cancer (OV) Models
Presenter: Keiji Furuuchi
Session: Poster Display session
5P - Physiologically relevant treatment models to investigate epigenetic mechanisms driving platinum resistance in ovarian High Grade Serous Carcinoma
Presenter: Raffaella Ergasti
Session: Poster Display session
6P - Unveiling the impact of intra-tumor heterogeneity in treatment response to achieve personalized medicine for endometrial cancer patients
Presenter: Beatriz Villafranca Magdalena
Session: Poster Display session